AD						

Award Number: W81XWH-11-1-0406

TITLE: Development of a Tetrathioether (S4) Bifunctional Chelate System for Rh-105

PRINCIPAL INVESTIGATOR: Valerie Carroll

CONTRACTING ORGANIZATION: University of Missouri Columbia, MO 65211-7600

REPORT DATE: July 2013

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY)	2. REPORT TYPE	3. DATES COVERED (From - To)
July 2013	Annual Summary	15 June 2012 - 14 June 201
4. TITLE AND SUBTITLE		5a. CONTRACT NUMBER
		W81XWH-11-1-0406
Development of a Tetrath	nioether (S4) Bifunctional Chelate	5b. GRANT NUMBER
System for Rh-105		W81XWH-11-1-0406
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S) Valerie Carroll, Don Wycoff, Gary	Sieckman, Fabio Gallizzi, Timothy Hoffman, Silvia	5d. PROJECT NUMBER
Jurisson	2.	5e. TASK NUMBER
		5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NA University of Missouri Columbia, MO 65211-7600	ME(S) AND ADDRESS(ES)	8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGE	` ,	10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Resear Fort Detrick, MD 21701-5	5012	

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for public release; distribution unlimited

13. SUPPLEMENTARY NOTES

We have previously, in the first year of this award, synthesized a new rhodium tetrathioether bombesin analogue, $[Rh-S4-8Aoc-BBN(7-14)NH_2]^+$. During the current period of investigation the molecule was tested for receptor binding affinity to the BB2 receptor on human prostate cancer PC-3 cells. Rhodium-105 radiolabeling studies were carried out with the $S4-8Aoc-BBN(7-14)NH_2$ ligand system and also with other known chelate systems 3,3,3,3-S4-Diol, 3,3,3-S4-(COOH)₂. The $[Rh-S4-8Aoc-BBN(7-14)NH_2]^+$ was found to exhibit a high affinity for the BB2 receptor (IC₅₀ = 2.2 ± 0.3 nM) however high yields of the radiolabeled $[^{105}Rh-S4-8Aoc-BBN(7-14)NH_2]^+$ complex were not achieved under any conditions tested. To better understand these results, the 3,3,3-S4-Diol and 3,3,3-S4-(COOH) $_2$ were investigated. It was revealed that traditional radiolabeling techniques for $^{105}\mathrm{Rh}$ are not compatible with systems that contain a carboxylic acid group.

15. SUBJECT TERMS

Rhodium, Bombesin, Tetrathioether, Radiopharmaceutical, Targeted Radiotherapy

16. SECURITY CL U	ASSIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
					USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE	UU	29	19b. TELEPHONE NUMBER (include area
U	U	U			code)

Table of Contents

Introduction	<u> Page</u> 4
Body	4
Key Research Accomplishments	26
Reportable Outcomes	27
Conclusion	27
References	28

Introduction:

Rhodium-105 is an interesting candidate for radiopharmaceutical use due to its nuclear emissions $(\beta^- = 566 \text{ keV}; \gamma = 319 \text{ keV } [19\%], 306 \text{ keV } [5\%])$ and kinetic stability. The goal of this project was to develop a new bombesin (BBN) targeted radiotherapeutic agent for 105 Rh using the bifunctional chelate technique. In pursuit of this objective, we have synthesized a new tetrathioether bombesin molecule, S4-8Aoc-BBN(7-14)NH₂, which may have implications for prostate cancer therapy. We have also investigated the use of cyclic and acyclic tetrathioether chelates with 105 Rh and the implications this chelate choice may have on radiopharmaceutical development. This work adds to the current knowledge of 105 Rh ligand systems and will aid future researchers in the selection criteria for viable chelate systems.

Body:

Specific Aim 3: IC₅₀ Evaluation of the non-radioactive [RhCl-S4-8Aoc-BBN]⁺ complex

Rhodium tetrathioether bombesin, [RhCl-S4-8Aoc-BBN(7-14)NH₂]⁺ was synthesized during the first year of this project. The previous annual report contains details of chelate synthesis, peptide coupling and formation of [RhCl-S4-8Aoc-BBN(7-14)NH₂]⁺. The affinity of [RhCl-S4-8Aoc-BBN(7-14)NH₂]⁺ for the gastrin releasing peptide receptor (type BB2) was evaluated using a competitive binding assay compared to ¹²⁵I-Tyr⁴-BBN with BB2 receptor positive PC-3 human prostate cancer cells. In a micro-well plate approximately 3 x 10⁵ PC-3 cells were suspended in Roswell Park Memorial Institute (RPMI) medium at pH 7.4 with 4.8 mg/mL HEPES, and 2 mg/mL BSA. The mixture was incubated at 37°C for 1 h with 30,000 cpm of ¹²⁵I-Tyr-BBN and increasing concentrations of [RhCl-S₄-BBN(7-14)NH₂]⁺ from 3.3x10⁻¹³ to 3.3x10⁻⁶ M. The cells were washed four times with media to release any non-specifically bound BBN and then counted on a Multi-Wiper (Laboratory Tecnologies, Maple Park, IL, USA) multiwell NaI gamma scintillation detector. The inhibitory concentration 50% (IC₅₀) was derived from the average of three experiments. The IC₅₀ curve (Figure 1) was obtained by plotting the % of ¹²⁵I-

Tyr-BBN bound to the cell as a function of the concentration of [RhCl-S₄-BBN(7-14)NH₂]⁺ added using GraphFit software version 4 (Erithacus Software Limited, Middlesex, UK).

The average concentration of [RhCl-S4-8Aoc-BBN(7-14)NH₂]⁺ needed to inhibit 125 I-Tyr⁴-BBN by 50% (IC₅₀) was determined to be 2.2 ± 0.3 nM. This value represents a significant improvement over the previously reported macrocyclic Rh-S₄- BBN(7-14)NH₂ (IC₅₀ = 37.5 \pm 10.5 nM) and Rh-S₄-5-Ava-BBN(7-14)NH₂ (IC₅₀ = 4.76 \pm 0.79 nM)^[1,2] and indeed is well within the range of recently investigated pre-clinical bombesin analogues for targeting prostate cancer.




Figure 1: [RhCl-S4-8Aoc-BBN(7-14)NH₂]⁺ vs ¹²⁵I-Tyr⁴-BBN competitive binding Assay.

*Specific Aim 4: Radiolabeling of the S4-8Aoc-BBN(7-14)NH*₂ *chelate.*

An ethanolic solution of S4-8Aoc-BBN(7-14)NH₂ was added to an aqueous solution of 0.5 - 1 mCi of rhodium-105 chloride at pH 3 - 4. Labeling conditions were varied from 2.5% - 57% ethanol and $5.8 \times 10^{-5} \text{ M} - 1.16 \times 10^{-3} \text{ M}$ S4-8Aoc-BBN(7-14)NH₂. In general, the following labeling conditions were investigated;


• 500 μ L (~ 1 mCi) of Rh-105, 100 μ L of 0.5 mg/mL S4-8Aoc-BBN(7-14)NH₂ in 15% ethanol.

Total ligand concentration: 5.8 x 10⁻⁵ M, Total ethanol: 2.5%

- 500 μ L (~ 1 mCi) of Rh-105, 100 μ L of 0.67 mg/mL S4-8Aoc-BBN(7-14)NH₂ in 15% ethanol. Total ligand concentration: 7.8 x 10⁻⁵ M, Total ethanol: 2.5%
- 20 μ L (~ 50 μ Ci) of Rh-105, 200 μ L of 0.67 mg/mL S4-8Aoc-BBN(7-14)NH₂ in 15% ethanol. Total ligand concentration: 4.2 x 10⁻⁴ M, Total ethanol: 13.6%
- 0.05 mg lyophilized S4-8Aoc-BBN(7-14)NH₂ in 50 μL acetonitrile, 100 μL ethanol 200 μL (~ 1 mCi) of Rh-105 stock
 Total ligand concentration: 9.46 x 10⁻⁴ M, Total ethanol: 28.5%
- 0.067 mg lyophilized S4-8Aoc-BBN(7-14)NH₂ in 50 μL acetonitrile, 100 μL ethanol 100 μL (~ 0.5 mCi) of Rh-105 stock
 Total ligand concentration: 1.84 x 10⁻⁴ M, Total ethanol: 40%
- 0.067 mg lyophilized S4-8Aoc-BBN(7-14)NH $_2$ in 50 μ L acetonitrile, 200 μ L ethanol 100 μ L (~ 1 mCi) of Rh-105 stock. (200 μ L was concentrated to 100 μ L at 90°C, N $_2$) Total ligand concentration: 1.33 x 10 4 M, Total ethanol: 57.1%
- 0.5 mg lyophilized S4-8Aoc-BBN(7-14)NH₂ in 100 μL acetonitrile, 100 μL ethanol 100 μL (~ 0.5 mCi) of Rh-105 stock
 Total ligand concentration: 1.16 x 10⁻³ M, Total ethanol: 33%

After 1 h of heating at 80°C, all of these conditions resulted in low labeling yields (< 5 - 10%) as measured by analytical HPLC (Figure 2, a). Additional heating (85 °C, 2 h) resulted in formation of many radiolabeled species also observed by HPLC (Figure 2 b and c). The multiple products likely resulted from both hydrolysis of amide bonds on the peptide due to excess heat and from the existence of multiple ¹⁰⁵Rh-S4 species. For comparison, analytical HPLC chromatograms of non-radioactive S4-8Aoc-BBN(7-14)NH₂ (Figure 3, a) and [RhCl-S4-8Aoc-BBN(7-14)NH₂]⁺ (Figure 3, b) using the same solvent gradient, column and system are included below. To better understand the results we encountered with radiolabeling ¹⁰⁵Rh-S4-8Aoc-BBN(7-14)NH₂, the ¹⁰⁵Rh-S4 chemistry with cyclic 3,3,3-S4-Diol^[3] and acyclic 3,3,3-S4-(COOH)₂^[4-6] chelate systems was revisited.

(A) 105 Rh-S4-8Aoc-BBN (7-14) NH $_2$ heated 1 h






Figure 2: Representative HPLC radio chromatogram of ¹⁰⁵Rh-S4-8Aoc-BBN(7-14)NH₂ for (a) 1 h heat at 80°C, (b) 2 h heat at 80°C, and (c) 2h heat with a spike of non-radioactive RhCl₃•3H₂O.

(A) 3, 3, 3-S4-8Aoc-BBN (7-14) NH₂




Figure 3: HPLC chromatogram of (a) 3,3,3-S4-8Aoc-BBN(7-14)NH₂ and (b) [RhCl-S4-8Aoc-BBN(7-14)NH₂]⁺ prepared on a macroscopic scale.

The macrocyclic 3,3,3,3-S4-Diol investigated by Venkatesh et al.^[3] is a well-known chelate for ¹⁰⁵Rh. This complex has been shown to provide >90% yields with ¹⁰⁵Rh via a quick labeling procedure and has previously been well characterized by silica gel TLC. Until recently 3,3,3,3-S4-Diol has been available commercially. For this reason many researchers studying new chelate systems for ¹⁰⁵Rh have used the ¹⁰⁵Rh-S4-Diol labeling procedure and analysis as a quick quality control procedure to determine the labeling efficiency of ¹⁰⁵Rhodium Chloride. We have elaborated on the previous TLC evaluation to include an HPLC method of evaluation. This new analysis has provided interesting results pertaining to labeling of thioether complexes with ¹⁰⁵Rh.

Non-radioactive RhCl₂-S4-Diol was prepared following the procedure reported by Venketesh^[3]. Briefly $0.80 \text{ mL}(3.0 \text{ x } 10^{-6} \text{ mol})$ of a 1.0 mg/mL solution of RhCl₃·3H₂O in acetonitrile was added to $1.0 \text{ mL}(3.0 \text{ x} 10^{-6} \text{ mol})$ of a 1.0 mg/mL solution of 3.3.3.3-S4-Diol in either 10% Ethanol/H₂O or 10% Ethanol/Saline at pH 4. The solution was heated at 80% for 1 h. Formation of chelated Rh-S4-Diol was confirmed by mass spectrometry. The macroscopic Rh-S4-Diol complex was evaluated by HPLC using a Waters Symmetry Shield RP-18 column (5 μ m, 4.6 x 250 mm) with binary gradient where A is increased from 1% to 90% over 8 min, remains linear at 90% until 9 min and is decreased from 90% back to 1% by 10 min.

The radiolabeled 105 Rh-S4-Diol was synthesized according to the previously published procedure. $^{[22]}$ Briefly, $100~\mu$ L ($3.0~x~10^{-4}$ mol) of a 0.1~mg/mL solution of 3,3,3-S4-Diol in 15% Ethanol/H $_2$ O was added to $500~\mu$ L (1~-2~mCi) of 105 Rh Chloride at pH 4 and heated for 1 h at $80~^{\circ}$ C. The resulting solution was spotted on a silica gel TLC plate and developed in 0.9% saline. The labeling solution was also evaluated using the HPLC method described above and compared to macroscopic results.

A 40 μ L aliquot of the reaction mixture described above was also spiked with 20 μ L (3.8 x 10⁻⁵ mol) of cold 1 mg/mL RhCl₃·3H₂O and heated for an additional hour at 80 °C. Again this mixture was analyzed using HPLC allowing for in situ confirmation of radio chromatographic peaks with species observed via UV detection.

HPLC analysis of the non-radioactive Rh-S4-Diol complex prepared in a pH 3 aqueous ethanolic solution resulted in a single peak with a retention time of 5.65 min using a gradient of 1% B – 90% B over 8min (Figure 4, c). However analysis of the radiolabeled ¹⁰⁵Rh-S4-Diol exhibited two peaks under the same HPLC conditions, one at 5.81 min and a second peak at 5.53 min (Figure 4, d). A second non-radioactive Rh-S4-Diol complex was prepared in pH 3 ethanolic solution with excess NaCl. HPLC analysis of this solution revealed two peaks at 5.54 min and 5.80 min (Figure 4 e). ESI-MS evaluation (Figure 5) of the macroscopic solutions indicates the presence of both *trans*-[Rh(OH)₂-S4-Diol]⁺ (m/z = 464.92 Da, calc = 464.98 Da) (Figure 5, a) and *trans*-[RhCl₂-S4-Diol]⁺ (m/z = 500.97 Da, calc = 500.91 Da) (Figure 4 b) based on the proposed structures (Figure 6).

This new data provides valuable information about the impact of reaction conditions on the species of *trans*-RhX₂-S4-Diol formed and indicates that the radiotracer chemistry of ¹⁰⁵Rh complexes must be carefully evaluated for multiple isomers when halides are coordinated to the metal center. In the presence of a reducing agent such as ethanol, the coordinated halides are fairly labile and may be exchanged. Additionally, the HPLC method developed represents a new quantitative QC method for future researchers to analyze ¹⁰⁵Rh chloride labeling efficiency.




Figure 4: Summary of Rh-S4-Diol HPLC analysis.

Minutes

О




Figure 5: ESI-MS evaluation of Rh-S4-Diol prepared in saline.

Figure 6: Macroscopic species, Rh(OH)₂-S4-Diol (a) and RhCl₂-S4-Diol (b).

*Investigation of the 3,3,3-S4-(COOH)*₂ *chelate system*

The 3,3,3-S4-(COOH)₂ ligand system previously studied by Goswami et al. ^[4-6] is most similar to our S4-8Aoc-BBN(7-14)NH₂ molecule. Using 3,3,3-S4-(COOH)₂ as a starting material, S4-8Aoc-BBN(7-14)NH₂ is formed by coupling the bombesin peptide to one of the carboxylate pendant groups on 3,3,-S4-(COOH)₂. Goswami et al. reports formation of a single radiolabeled *trans*-[¹⁰⁵RhCl₂-S4-(COOH)₂]⁺ species as evaluated by silica gel thin layer chromatography (TLC) in which the product does not move from the origin; only ¹⁰⁵Rh chloride moves with the solvent front in saline. ^[4-6] Based on the results observed for *trans*-RhX₂-S4-Diol, it was suspected that a number of Rh-S4-(COOH)₂ species were possible for this preparation as well and therefore a more quantitative analysis was performed using HPLC, mass spectrometry and NMR.

Non-radioactive Rh-S4-(COOH)₂ was prepared in ethanolic solutions with and without excess NaCl analogous to the Rh-S4-Diol preparation described above and analyzed by the same HPLC procedure. In the absence of excess NaCl the primary Rh(III) species formed is the mono chloride species, [RhCl-S4(COOH)(COO')]⁺ with one coordinated pendant carboxylate group (m/z = 508.83 Da, calc = 508.92 Da) (Figure 7, a). This species is observed at an HPLC retention time of 6.14 min (Figure 8, b). When prepared with excess NaCl present the two species observed are *trans*-[RhCl₂-S4-(COOH)₂]⁺ (m/z = 544.93 Da, calc = 544.90 Da) (Figure 7, b) with a retention time of 6.87 min (Figure 8, c) and [RhCl-S4(COOH)(COO')]⁺ with a retention time of 6.26 min (Figure 8, c). As previously discussed, in the presence of ethanol the coordinated chlorides are readily exchanged. If chloride ions (i.e., salt, NaCl) are not present in sufficient concentration, the coordinated chloride may exchange for another nearby donor atom, in this case a pendant carboxylate.




Figure 7: Initial species observed in initial macroscopic preparations.

(A) 3,3,3-S4-(COOH)2 Ligand Waters RP-18 1% - 90% B 8min mVolts - 1000 (B) $RhX_2-S4-(COOH)_2$ prepared no salt mVolts - 10€00 (C) $Rh-S4-(COOH)_2$ prepared in saline m/olts - 50€ (D) 105 RhX₂-S4-(COOH)₂ m/olts -2 sllo/li (E) $^{105}\text{RhX}_2\text{-S4-(COOH)}_2$ spiked with cold RhCl $_3$, heated 1h m/olts

Figure 8: Summary of trans-RhX₂-S4-(COOH)₂ HPLC analysis

Since the existence of at least two *trans*-[RhX₂-(COOH)₂]⁺ species has been confirmed on a macroscopic scale, it is necessary to evaluate the radiotracer behavior. The 105 Rh chloride stock solution is in dilute HCl (pH ~ 1) following separation from the 104 Ru target material at the University of Missouri Research Reactor (MURR). Before labeling, this sample is adjusted to pH 3-4 with 0.1 M NaOH, which generates NaCl. We hypothesized that radiolabeling of the S4-(COOH)₂ ligand under these conditions would result in predominately the *trans*-[RhCl₂-S4-(COOH)₂]⁺ species. However HPLC analysis of the radiolabeling reaction mixture revealed at least 4 different peaks with retention times of 4.87 min, 5.71 min, 6.24 min and 6.82 min (Figure 8, d). The radiolabeled mixture was spiked with non-radioactive RhCl₃· 3H₂O and heated for an additional hour. This test generates "carrier" Rh-S4-(COOH)₂ compounds in macroscopic amounts, which can be observed by UV (λ = 220 nm) to confirm a radiochromatographic peak and will highlight any differences between chemistry that occurs on the tracer level and chemistry that occurs on the macroscopic level under the same conditions. The UV trace confirmed all 4 of the tracer peaks observed (Figure 8, e). It is clear that under these conditions it is possible to make multiple Rh-S4-(COOH)₂ species.

At this point, we hypothesized that the additional peaks by HPLC may be due to any combination of dichloro, dihydroxo, and pendant carboxylate coordinated *trans*-RhX₂-S4-(COOH)₂ species.

During the initial macroscopic evaluation of trans-[RhX₂-S4-(COOH)₂]⁺ two species were observed where either $X_2 = Cl_2$ ($t_r = 6.87$ min) or $X_2 = Cl$, pendant COO^- ($t_r = 6.14$ min) depending on the concentration of NaCl present in solution. Using the published radiolabeling conditions^[4,6] more than two trans-[105 RhX₂-S4-(COOH)₂]⁺ species were observed by HPLC ($t_r = 4.87$ min, 5.71 min, 6.24 min and 6.82 min). It was suspected that the trans-[Rh(OH)₂-S4-(COOH)₂]⁺ species might also be possible in a manner analogous to the observed trans-[Rh(OH)₂-S4-Diol]⁺ when water is present. Therefore reaction conditions varying the amount of water present and the amount of salt present were investigated.

In order to identify as many Rh-S4-(COOH)₂ species as possible, the complex was formulated under a series of reaction conditions all at pH 3: (1) all organic solvent reaction conditions (50% ethanol/acetonitrile), (2) an organic solvent system with excess NaCl (saturated), (3) an aqueous-organic solvent mixture (25% water, 25% ethanol, 50% acetonitrile) and (4) an aqueous solution with excess NaCl (0.1 g). All reaction mixtures were heated for 1 h at 80°C, cooled, and then analyzed using the same HPLC method described above. The reaction mixtures were then lyophilized and taken up in either 50% acetonitrile/water for ESI-MS evaluation or 50% d₃-acetonitrile/D₂O for NMR studies.


HPLC evaluation (Waters RP-18, 1% B - 90% B over 8 min) of sample (1) prepared in 50% ethanol/acetonitrile resulted in a primary peak with a retention time of 6.20 min. Sample (2) prepared in 50% ethanol/acetonitrile saturated with NaCl resulted in a primary peak with a retention time of 6.19 min. The solubility of NaCl in ethanol and acetonitrile is low, 0.65 g/kg and 0.003 g/kg respectively. Thus the conditions in these two preparations are quite similar and similar HPLC results are not surprising.


The macroscopic synthesis of *trans*-[RhCl₂-S4-(COOH)₂]⁺ previously reported^[4,5] was carried out in acetonitrile/ethanol solution. The radiotracer synthesis is carried out quite differently because of the aqueous starting solution available for ¹⁰⁵Rh-chloride following separation from its target. Our macroscopic preparation of samples (3) prepared in 25% water, 25% ethanol, 50% acetonitrile and (4) prepared in 25% water, 25% ethanol, 50% acetonitrile with 0.1 g NaCl are more similar to radiolabeling conditions.

HPLC evaluation of sample (3) prepared in 25% water, 25% ethanol, 50% acetonitrile resulted in a broad peak (or group of overlapping peaks) with retention times of $\sim 5.06 - 6.54$ min. Within this region two significant peaks are observed with retention times of 5.68 min and 6.21min. Under these conditions it appears that many species are formed.


Evaluation of sample (4) prepared in 25% water, 25% ethanol, 50% acetonitrile with 0.1 g NaCl resulted in a primary peak with a retention time of 6.18 min. This result suggests that addition of excess NaCl may be used to encourage formation of a single predominate species.

The amount of NaCl present during radiotracer formulation of *trans*-[¹⁰⁵RhX₂-S4-(COOH)₂]⁺ is currently unknown. During separation of ¹⁰⁵Rh from ^{104/105}Ru, significant amounts of NaCl are generated by the addition of HCl to a mixture of NaOCl and NaOH. The NaOCl was generated *in situ* by bubbling of Cl₂ gas into NaOH. Since it is unknown how much NaOCl is generated at this step, the amount of NaCl generated by addition of acid to the separation solution is also unknown. It is possible that the concentration of NaCl present in our radiolabelling formulation is less than the amount present (0.025 mg/mL) in sample (4). Addition of more salt to the radiolabeling solution may improve the yield of a single (or more predominate) species.






Sample (2) 50% Ethanol/Acetonitrile + NaCl



Sample (3) 25% Water/25% Ethanol/50% Acetonitrile



Sample (4) 25% Water/25% Ethanol/50% Acetonitrile + NaCl




Figure 9: HPLC analysis of samples prepared under reaction conditions 1-4.

The lyophilized *trans*-[RhX₂-S4-(COOH)₂]⁺ was taken up in d₃-acetonitrile and evaluated by NMR. The presence of multiple isomers of the product will result in a complex spectrum with overlapping peaks, especially in the regions for the three propylene backbone protons. However, the methylene group on the terminal thioethers should be observed as singlets if the carboxylate group is not coordinated and a doublet of doublets (each proton unique) if it is coordinated to the Rh center.

Based on ¹HNMR and COSY analysis it is evident that multiple Rh-S4-(COOH)₂ species are present in each of the samples. 3,3,3-S4-(COOH)₂ is a symmetrical molecule. Each H is chemically equivalent to the corresponding H in the other half of the molecule (across the plane of symmetry). Thus the ¹HNMR spectraum of the uncomplexed 3,3,3-S4-(COOH)₂ chelate shows relatively few peaks (Figure 10). Upon complexation with Rh chloride, if there were only one *trans*-RhCl₂-S4-(COOH)₂ species produced with a single isomer, as previously believed, one would not expect any increase in the number of peaks observed, only a change in chemical shifts. ¹HNMR evaluation of the RhX₂-S4-(COOH)₂ complexes formed when prepared in aqueous solutions results in the appearance of many additional peaks. This is indicative of the presence of multiple RhX₂-S4-(COOH)₂ species (Figure 11), some of which may involve coordination to a pendant carboxylate group. Species with a coordinated carboxylate do not have a plane of symmetry. Each H on the molecule is chemically unique, and therefore a more comples spectrum (many more peaks) can be expected.

It is not possible to identify any species based on this ¹HNMR evaluation, but it is clear that multiple species are present. The multiple overlapping peaks can be explained by either formation of additional *trans*-RhX₂-S4-(COOH)₂ species (all differing in X₂ coordinated atoms) and/or the existence of more than one isomer of *trans*-RhX₂-S4-(COOH)₂.






Figure 10: ¹HNMR of 3,3,3-S4-(COOH)₂ ligand.

sample 3 - H2O




Figure 11: ¹HNMR analysis of *trans*-[RhX₂-S4-(COOH)₂]⁺ prepared in an aqueous solution.

Using ESI-MS several compounds were identified based on proposed structures as summarized in Figure 12 and Table 1. Samples employing reaction conditions (1) and (2) were very similar. Both were prepared in 50% ethanol/acetonitrile, sample (2) with the addition of excess NaCl. Under these conditions, RhCl₂-S4-(COOH)₂ (m/z = 544.91 Da, calc = 544.90 Da) (Figure 12 a) and RhCl₂-S4-(COOH)(COOEt) (m/z = 572.89 Da, calc = 572.93 Da) (Figure 12 b) were predominant and to a somewhat lesser extent RhCl-S4-(COOH)(COO-) where a pendant carboxylate group is coordinated to the metal center (m/z = 508.87 Da, calc = 508.92 Da) (Figure 12 d) is also observed (Figures 13 and 14). The ethyl ester (Figure 12, b) is formed by acid catalyzed esterification in the presence of ethanol.

In sample (4) under aqueous conditions with excess NaCl the formation of RhCl₂-S4-(COOH)₂ (m/z = 544.91 Da, calc = 544.90 Da) (Figure 12 a) is dominant. However small amounts of RhCl-S4-(COOH)(COO-) (m/z = 508.87 Da, calc = 508.92 Da) (Figure 12 d), RhCl₂-S4-(COOH)(COOEt) (m/z = 572.89 Da, calc = 572.93 Da) (Figure 12 b) and RhCl₂-S4-(COOEt)₂ (m/z = 600.91 Da, calc = 600.96 Da) (Figure 12 c) are also present (Figure 16).

The presence of all five species was observed in sample (3) prepared in aqueous conditions (25% water, 25% ethanol, 50% acetonitrile no salt). A significant yield of all three species RhCl₂-S4-(COOEt)₂ (m/z = 600.91 Da, calc = 600.96 Da) (Figure 12 c), RhCl-S4-(COOH)(COO-) (m/z = 508.87 Da, calc = 508.92 Da) (Figure 12 d), and RhCl-S4-(COOEt)(COO-) (m/z = 536.90 Da, calc = 536.95 Da) (Figure 12 e) was observed (Figure 15). This is the only sample in which the monochloro pendant carboxylate coordinated RhCl-S4-(COOEt)(COO-) species was observed with a pendant ethyl ester. We had hypothesized that a Rh(OH)₂-S4-(COOH)₂ species analogous to the observed Rh(OH)₂-S4-Diol may be present in aqueous solutions without NaCl, however this species was not observed.

There is a significant difference between sample (3), which was prepared in a solution of 25% water, 25% ethanol, 50% acetonitrile, and sample (4), which was prepared in the same solution with the

addition of 0.1 g NaCl. Without the presence of excess chloride ions in solution the pendant coordinated monochloride species RhCl-S4-(COOH)(COO-) and RhCl-S4-(COOEt)(COO-) are favored in addition to other species. With the presence of excess chloride ions in solution the dichloro species especially RhCl₂-S4-(COOH)₂ are more favored. The solvents used in radiolabeling are aqueous and it is likely that the concentration of NaCl present during radiolabeling is in between the conditions in samples (3) and (4). Therefore the addition of more NaCl might favor the production of a more dominate single ¹⁰⁵RhX₂-S4-(COOH)₂ species.

The pendant ethyl esters on species (b), (c) and (e) (Figure 12) are formed by acid catalyzed Fischer esterification of the pendant carboxylic acid. An acidic solution is required to prevent the formation of 105 Rh(OH)₃ and ethanol is required as a reducing agent. If neither acid nor ethanol can be eliminated, the formation of ethyl esters will continue to be a competing reaction for this formulation. The results of this study indicate that traditional radiolabeling techniques used for 105 Rh are not compatible with molecules that contain carboxylic acid groups.




Figure 12: Rh-S4-(COOH)₂ species identified in samples 1-4.

Sample	Reaction Conditions	Products observed
1	50% ethanol/acetonitrile	a , b , d
2	50% ethanol/acetonitrile + NaCl	a , b , d
3	25% water, 25% ethanol, 50% acetonitrile	a, b, c , d , e
4	25% water, 25% ethanol, 50% acetonitrile + NaCl	a , b, c, d

 Table 1: Products observed for various reaction conditions




Figure 13: Rh-S4-(COOH)₂ Sample (1) prepared in 50% ethanol/acetonitrile.




Figure 14: Rh-S4-(COOH)₂ Sample (2) prepared in 50% ethanol/acetonitrile + NaCl.




Figure 15: Rh-S4-(COOH)₂ Sample (3) prepared in 25% water, 25% ethanol, 50% acetonitrile.




Figure 16: Rh-S4-(COOH)₂ Sample (4) prepared in 25% water, 25% ethanol, 50% acetonitrile + NaCl.

Specific Aim 5: Animal biodistribution studies

Animal biodistribution studies could not be carried out since a high yield of a single conformer of [105 RhX $_2$ -S4-8Aoc-BBN(7-14)NH $_2$] $^+$ could not be obtained. Indeed recent studies indicate that formation of a single species cannot be formed with any chelate that contains a carboxylic acid group using traditional radiolabeling techniques for 105 Rh.

Specific Aim 6: Present and publish results

This work has been published in the form of a Ph.D. thesis and has also been prepared in paper form to be submitted for publication in the near future.

Training Program

Over the past year this grant has provided me with many opportunities to develop my career. In the fall semester I took Biochem 4460 – Cancer Biology in addition to my previously completed course work in chemistry. This class provided me with additional material to diversify my training as a translational scientist in the field of Cancer Research. This year, and throughout my graduate studies, I have attended symposia offered by the University of Missouri Chemistry Department and the Radiopharmaceutical Sciences Institute. I have benefited from one on one mentoring with leaders in the field of Radiopharmaceutical Chemistry, Dr. Silvia Jurisson and Dr. Timothy Hoffman. I successfully completed my degree in May 2013, earning a Ph.D. in chemistry based on research supported by this grant. I have accepted a postdoctoral position with Dr. David Wilson at University of California San Francisco, where I plan to continue my work as a prostate cancer researcher focusing on the development of redox sensitive positron emission radiotracers.

Key Research Accomplishments:

• Synthesized a new rhodium tetrathioether molecule with high affinity for the BB2 receptor on human prostate cancer PC-3 cells

- Developed a new quantitative QC method for analyzing radiolabeling efficiency of rhodium-105
- Analyzed the effect of chloride ion concentration in labeling solutions of final radiolabled 105Rh tetrathioether products for cyclic (3,3,3,3-S4-Diol) and acyclic (3,3,3-S4-(COOH)2 chelate systems.
- Discovered that traditional rhodium-105 radiolabeling techniques are not compatible with molecules that contain a carboxylic acid group.

Reportable Outcomes:

Presentations

Carroll, V; Wycoff, D; Sieckman, G; Hoffman, T; Jurisson, S; "Synthesis of a ¹⁰⁵Rh tetrathioether bombesin molecule for prostate cancer therapy" 243rd National Meeting of the American Chemical Society: San Diego, CA, March 25 – 29, 2012

Manuscripts

Carroll, V; Demoin, D; Hoffman, T; Jurisson, S; *Inorganic Chemistry in Nuclear Imaging and Radiotherapy: Current and Future Directions.* Radiochimica Acta, 2012. **100:** p. 653 – 667

Carroll, V; Development of a Rhodium Tetrathioether Bombesin Analogue and Investigation of Cyclic and Acyclic Ligand systems for ¹⁰⁵Rh(III). Ph. D. Thesis, Department of Chemistry. 2013, University of Missouri. p. 94

Carroll, V; Wycoff, D; Sieckman, G; Gallazzi, F; Hoffman, T; Jurisson, S; Synthesis of a Rh tetrathioether bombesin analogue and impact of labeling conditions on chelate systems with pendant carboxylate groups, (in preparation)

Degrees Obtained

Ph.D. in Chemistry, University of Missouri, May 2013

Employment Opportunities Received

Postdoctoral Scholar, University of California San Francisco, Department of Radiology and Biomedical Imaging, Mentor: Dr. David Wilson

Conclusion:

We have successfully synthesized a novel rhodium bombesin conjugate, [RhCl-S4-8Aoc-BBN(7-14)NH₂] $^+$. In vitro evaluation indicates high affinity for PC-3 human prostate cancer cells however low radiochemical yields of a single [105 Rh-S4-8Aoc-BBN(7-14)NH₂] $^+$ species on the radiotracer scale may preclude its usefulness as a radiotheraputic agent. The pendant carboxylic acids were thought to be useful for maintaining reasonable hydrophilicity and thus clearance through the renal system. However, pendant carboxylic acids resulted in both complexes with a coordinated carboxylate and in esterification, the latter

is particularly a problem at the radiotracer level where acidic ethanolic reaction conditions are needed. In place of an acyclic bifunctional chelate (BFC) system with a pendant carboxylic acid, it is recommended to change the direction of research in future studies to investigate cyclic BFC's or acyclic BFC's with a methyl ester or methyl ether pendant group. This will prevent the formation of ethyl esters during radiolabeling.

Refrences:

- 1. Li, N., Synthesis and characterization of ¹⁰⁵Rh-labeled thiamacrocycles for use to formulate peptide receptor agents, in Department of Chemistry. 1996, University of Missouri. p. 141.
- 2. Li, N., et al., *Biodistribution of model 105Rh-labeled tetradentate thiamacrocycles in rats.* Nuclear Medicine and Biology, 1997. **24**(1): p. 85-92.
- 3. Venkatesh, M., et al., An Rh-105 complex of tetrathiacyclohexadecane diol with potential for formulating bifunctional chelates. Nuclear Medicine and Biology, 1996. **23**(1): p. 33-40.
- 4. Goswami, N., ¹⁰⁵Rh(III) Complexes With Acyclid Tetrathioether Ligands: Potential Radiotherapeutic Agents, in Department of Chemistry. 1996, University of Missouri. p. 160.
- 5. Goswami, N., et al., *Rhodium(III) Complexes with Acyclic Tetrathioether Ligands. Effects of Backbone Chain Length on the Conformation of the Rh(III) Complex.* Inorganic Chemistry, 1996. **35**(26): p. 7546-7555.
- 6. Goswami, N., et al., *Rhodium-105 tetrathioether complexes: radiochemistry and initial biological evaluation.* Nuclear Medicine and Biology, 1999. **26**(8): p. 951-957.